Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Open-label Staggered Dose-escalation and Observer-blind Expansion Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Multicomponent Vaccine mRNA-1365 (Profile 2 [RSV and hMPV]) in Healthy Adults ≥60 Years of Age

NCT07764237 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07764237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Open-label Staggered Dose-escalation and Observer-blind Expansion Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Multicomponent Vaccine mRNA-1365 (Profile 2 [RSV and hMPV]) in Healthy Adults ≥60 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 11, 2026
Completion date
July 20, 2027
Enrollment
375 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

human metapneuomovirus (hmpv), respiratory syncytial virus (rsv)